

Executive Officer Notice: End of Funding of Braftovi[®] (encorafenib) and Vectibix[®] (panitumumab) in the treatment of treatment-naïve patients with BRAF V600E-mutated metastatic colorectal cancer

October 30, 2026

Braftovi[®] (encorafenib) used within a first line combination regimen for the treatment of BRAF V600E-mutated metastatic colorectal cancer, was funded for eligible patients in Ontario, in combination with Vectibix[®] (panitumumab), in accordance with certain criteria, effective May 13, 2026.

Public drug funding in Ontario for Braftovi[®] in the treatment of treatment-naïve patients followed an agreement reached through the Funding Accelerated for Specific Treatments (FAST) Pilot, which accelerates funding for selected high-priority cancer treatments.

While the standard pathway for drug funding waits for pan-Canadian pricing negotiations to complete prior to public funding, cancer drugs accelerated through the FAST pilot are funded while negotiations proceed.

In the event that public funding is not continued after the negotiations conclude, the drug manufacturer must fund the drug for patients who started publicly-funded treatment with the drug for the applicable indication.

On July 24, 2026, the pan-Canadian Pharmaceutical Alliance (pCPA) negotiations for Braftovi[®] ended with no agreement reached. As a result, Ontario will now be ending its public funding of Braftovi when used in combination with Vectibix[®] as a first line therapy for the treatment of BRAF V600E-mutated metastatic colorectal cancer (generally used with an EGFR inhibitor and mFOLFOX6), effective December 15, 2026.

Patients who have initiated publicly-funded treatment with Braftovi[®] in Ontario for the indication described above as of December 15, 2026, will continue to receive coverage for their treatment via the manufacturer's patient support program. Patients who have initiated publicly-funded treatment through the

New Drug Funding Program for Vectibix® (panitumumab) for the same indication as of December 15, 2026 will continue to receive coverage for Vectibix® under the New Drug Funding Program.

New approvals for Braftovi® and Vectibix® in the treatment of treatment-naïve patients as described above will not be issued after December 15, 2026.

More information on the ministry's FAST pilot can be found at:

<https://www.ontario.ca/page/funding-accelerated-specific-treatments-fast-pilot-program>

It should be noted that, in general, this does not impact patients using Braftovi® and Vectibix® in other publicly funded circumstances outside of the treatment of treatment-naïve patients with BRAF V600E-mutated metastatic colorectal cancer.

Additional information:**For pharmacies:**

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other health care providers and the public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282